StiRx Inc
Biotechnology company focused on development of vaccines and biologic therapeutics to prevent and treat sexually transmitted infections (STIs). The organization’s stated mission is to reduce STI-related morbidity and mortality and to develop alternatives to antibiotics by advancing vaccine candidates and antibody-based biologics against pathogens such as Neisseria gonorrhoeae and Chlamydia spp.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Long-acting monoclonal antibody candidate for gonorrhea (early-stage)
Preclinical development of a long-acting monoclonal antibody intended for treatment and immuno‑prophylaxis against gonococcal infection.
Gonococcal vaccine candidate (early-stage)
Preclinical vaccine candidate targeting Neisseria gonorrhoeae intended to prevent infection in at‑risk populations.
Bispecific antibody candidate for chlamydia (early-stage)
Preclinical bispecific antibody program directed at Chlamydia species with exploratory development for other STI treatments.
Long-acting monoclonal antibody candidate for gonorrhea (early-stage)
Preclinical development of a long-acting monoclonal antibody intended for treatment and immuno‑prophylaxis against gonococcal infection.
Gonococcal vaccine candidate (early-stage)
Preclinical vaccine candidate targeting Neisseria gonorrhoeae intended to prevent infection in at‑risk populations.
Bispecific antibody candidate for chlamydia (early-stage)
Preclinical bispecific antibody program directed at Chlamydia species with exploratory development for other STI treatments.
Services
Collaborative research agreements and memoranda of understanding with external institutes to advance biologic therapeutics for STIs.
Preparation and dissemination of research results through conference presentations and peer-reviewed articles.
Collaborative research agreements and memoranda of understanding with external institutes to advance biologic therapeutics for STIs.
Preparation and dissemination of research results through conference presentations and peer-reviewed articles.
Expertise Areas
- Vaccine development for sexually transmitted infections
- Monoclonal and bispecific antibody therapeutics
- Preclinical biologics pipeline management
- Infectious disease immunotherapeutics
Key Technologies
- Monoclonal antibody therapeutics
- Bispecific antibodies
- Vaccine platforms for bacterial STIs
- Long-acting biologic formulations
News & Updates
Company presented advances in biologic therapeutics for sexually transmitted infections at an industry congress.
Announcement of a memorandum of understanding with an external vaccine institute to advance monoclonal antibody technologies targeting drug‑resistant gonorrhea.
Company co‑founders authored a review article on biologic therapies for STIs published in Clinical Microbiology Reviews.
Announcement of planned presentation of research on gonorrhea therapeutics at a scientific meeting.
Company presented advances in biologic therapeutics for sexually transmitted infections at an industry congress.
Announcement of a memorandum of understanding with an external vaccine institute to advance monoclonal antibody technologies targeting drug‑resistant gonorrhea.
Company co‑founders authored a review article on biologic therapies for STIs published in Clinical Microbiology Reviews.
Announcement of planned presentation of research on gonorrhea therapeutics at a scientific meeting.